Zonisamide: newer antiepileptic agent with multiple mechanisms of action

Author: Biton, Victor

Source: Expert Review of Neurotherapeutics, Volume 4, Number 6, November 2004 , pp. 935-943(9)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Zonisamide (Zonegran^®, Eisai, Inc.) is a broad spectrum antiepileptic drug indicated for use as adjunctive therapy in the treatment of partial seizures. Zonisamide has multiple mechanisms of action, which may explain widespread reports of its utility in focal epilepsy and generalized epilepsy, and for nonseizure disorders such as headache and neuropathic pain. Zonisamide has been available in Japan since 1989 and became available in the USA in 2002. The rights to this drug in North America and Europe were recently acquired by Eisai Co. A review of the chemical properties, pharmacokinetics, metabolism, potential mechanisms of action, efficacy in seizure and nonseizure disorders, and tolerability was therefore thought to be timely.

Keywords: efficacy; epilepsy; neuropathic pain; pharmacokinetics; tolerability; zonisamide

Document Type: Drug Evaluation

DOI: http://dx.doi.org/10.1586/14737175.4.6.935

Publication date: 2004-11-01

More about this publication?

Expert Review of Neurotherapeutics provides expert commentary on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites